Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Pre-Treatment	STARTED	Radiotherapy, Temozolomide Plus Nivolumab	358
Pre-Treatment	STARTED	Radiotherapy, Temozolomide Plus Placebo	358
Pre-Treatment	COMPLETED	Radiotherapy, Temozolomide Plus Nivolumab	354
Pre-Treatment	COMPLETED	Radiotherapy, Temozolomide Plus Placebo	355
Pre-Treatment	NOT COMPLETED	Radiotherapy, Temozolomide Plus Nivolumab	4
Pre-Treatment	NOT COMPLETED	Radiotherapy, Temozolomide Plus Placebo	3
End of Treatment	STARTED	Radiotherapy, Temozolomide Plus Nivolumab	355
End of Treatment	STARTED	Radiotherapy, Temozolomide Plus Placebo	354
End of Treatment	COMPLETED	Radiotherapy, Temozolomide Plus Nivolumab	0
End of Treatment	COMPLETED	Radiotherapy, Temozolomide Plus Placebo	0
End of Treatment	NOT COMPLETED	Radiotherapy, Temozolomide Plus Nivolumab	355
End of Treatment	NOT COMPLETED	Radiotherapy, Temozolomide Plus Placebo	354

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02667587/flow